Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries

Cardiovascular Drugs and Therapy

Volumn 31, Issue 2, 2017, Pages 187-195

  Rosenson, Robert S ^a   Gandra, Shravanthi R ^b   McKendrick, Jan ^c   Dent, Ricardo ^b   Wieffer, Heather ^c   Cheng, Lung I ^b   Catapano, Alberico L ^d   Oh, Paul ^e   Kees Hovingh, G ^f   Stroes, Erik S ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

^c PRMA Consulting   (United Kingdom)

^d UNIVERSITY OF MILAN   (Italy)

^e TORONTO REHABILITATION INSTITUTE   (Canada)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Clinical practice; Hypercholesterolemia; Reduced statin tolerance; Statin associated muscle symptoms; Statin associated symptoms

Indexed keywords

AMINOTRANSFERASE; BEZAFIBRATE; CIPROFIBRATE; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRIA; BELGIUM; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; COLOMBIA; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROATIA; CROSS-SECTIONAL STUDY; CZECH REPUBLIC; DENMARK; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG RECHALLENGE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUSCLE DISEASE; PATIENT IDENTIFICATION; PHARMACEUTICAL CARE; PORTUGAL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RUSSIAN FEDERATION; SAUDI ARABIA; SIDE EFFECT; STATIN ASSOCIATED SYMPTOM; SWITZERLAND; SYMPTOM ASSESSMENT; TURKEY (REPUBLIC); UNITED ARAB EMIRATES; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SUBSTITUTION; EUROPE; HEALTH CARE SURVEY; MULTICENTER STUDY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SKELETAL MUSCLE;

COLOMBIA; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; EUROPE; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCLE, SKELETAL; MUSCULAR DISEASES; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SAUDI ARABIA; UNITED ARAB EMIRATES;

EID: 85018413633     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-017-6727-0     Document Type: Article

References (18)

1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Atherosclerosis. 2016;252:207–74.
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis. 2016;253:281–344.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.
4. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.
5. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34.
6. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013;23(9):871–5.
7. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761–70.
8. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.
9. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32(7 Suppl):S35–65.
10. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment. Aetiology and Management Eur Heart J. 2015;36(17):1012–22.
11. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71.
12. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.
13. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684–98.
14. Serban M-C, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–95.
15. Gulizia MM, Colivicchi F, Arca M, Abrignani MG, Perna GP, Mureddu GF, et al. ANMCO position paper: diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance. G Ital Cardiol (Rome). 2016;17(6):447–55.
16. Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81.
17. Hovingh GK, Gandra SR, McKendrick J, Dent R, Wieffer H, Catapano AL, et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis. 2016;245:111–7.
18. Rosenson RSM K, Bayliss, M., Sanchez, R., Baccara-Dinet, M.T., Chibedi-De-Roche, D, Taylor, B., Khan, I., Manvelian, G., White, M., Jacobson, T.A. The Statin-Associated Muscle Symptom (SAMS) Clinical Index: Revision for clinical use, content validation, and inter-rate reliability. Cardiovasc Drugs Ther. 2017;31.